Blossomhill Therapeutics priced a $150 million IPO to fund its macrocyclic cancer drug pipeline, including next-generation inhibitors aimed at oncology targets such as EGFR-mutant non-small-cell lung cancer. The company upsized its share count compared with its earlier plans and priced at the low end of the $16-to-$18 range, consistent with the current IPO market pattern. Macrocyclic chemistry has been used to improve selectivity and binding properties for difficult targets, and the company’s financing is directed toward advancing its inhibitor series across additional oncology indications. IPO proceeds are expected to support both clinical expansion and platform iteration for structure-activity work. Blossomhill’s move further highlights how investors are funding chemistry-focused oncology platforms during a period of heightened IPO activity in 2026.